Gene or Genome
AstraZeneca’s New Calquence Combinations Show Promise in CLL Treatment: Potential to Shift Clinical Practice
AstraZeneca, Calquence, CLL, Chronic Lymphocytic Leukaemia, BTK Inhibitor, Venetoclax, Obinutuzumab, Clinical Practice, Fixed-Duration Treatment
BioMarin’s Brineura Receives Significant Label Expansion from FDA for Children Under 3 with CLN2 Disease
BioMarin, Brineura, FDA, Label Expansion, CLN2 Disease, Children Under 3, Cerliponase Alfa, Intraventricular Injection, Motor Ability Deterioration, Neurodegenerative Symptoms
RAPT Therapeutics Announces Significant Workforce Reduction Following Clinical Hold on Zelnecirnon Trials
RAPT Therapeutics, zelnecirnon, clinical hold, workforce reduction, FDA, clinical trials, atopic dermatitis, asthma, oncology, CCR4 agonist
SciRhom Secures €63 Million in Series A Funding for Autoimmune Therapies
SciRhom, autoimmune diseases, iRhom2, therapeutic strategy, Series A funding, biotech, pharmaceuticals
UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data
UniQure, Huntington’s disease, gene therapy, AMT-130, FDA, RMAT designation, Phase I/II clinical trials, neurodegenerative disorder, neurofilament light (NfL), disease progression, composite Unified Huntington’s Disease Rating Scale (cUHDRS).
US Government Appeals Jury Decision in High-Stakes HIV PrEP Patent Battle Against Gilead
HIV, PrEP, Patent Battle, Gilead, Truvada, Descovy, US Government, Patent Litigation
Roche’s TIGIT Drug Tiragolumab Fails Another Phase 3 Lung Cancer Trial
Roche, TIGIT, tiragolumab, lung cancer, Phase 3 trial, failure, Keytruda, Tecentriq
Alumis Completes IPO, Raising $250 Million for Inflammation and Immunology Research
Alumis, IPO, Inflammation, Immunology, Biotech, TYK2 Inhibitor, Plaque Psoriasis, Uveitis, Lupus
Lykos Faces Setback as ICER Concludes Insufficient Evidence for MDMA-Based PTSD Treatment
Lykos Therapeutics, MDMA, PTSD, ICER, Insufficient Evidence, Clinical Trials, FDA Approval
Arc Institute Unveils Revolutionary Bridge Editing Technology for Programmable Genome Design
Bridge editing, genome design, programmable gene editor, DNA strands, Arc Institute, CRISPR, RNA-guided systems, genetic engineering